Inhibition of MCF-7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs

Lian Lian, Wei Li, Zhen Yu Li, Yi Xiang Mao, You Tao Zhang, Yi Ming Zhao, Kai Chen, Wei Ming Duan, Min Tao

Research output: Contribution to journalArticlepeer-review

51 Scopus citations

Abstract

Cancer metastasis is a highly coordinated and dynamic multistep process in which cancer cells interact with a variety of host cells. Morphological studies have documented the association of circulating tumor cells with host platelets. Tumor cell-induced platelet aggregation (TCIPA) contributes significantly to hematogenous metastasis; however, the molecular mechanisms involved in breast cancer TCIPA are poorly characterized. In this study, MCF-7 metastatic human breast cancer cells induced dose-dependent aggregation of washed platelets. Four major platelet activation pathways, glycoprotein (GP)-Ib-IX, GPIIb/IIIa, thromboxane (TX)-A2 and adenosine diphosphate (ADP) were activated during TCIPA and were inhibited by their respective inhibitors, 7E3, SZ-1, aspirin and apyrase. Pretreatment of platelets with 7E3, SZ-1 or apyrase significantly inhibited TCIPA, while pretreatment with aspirin had no effect. Moreover, combined pretreatment of platelets with 7E3, SZ-1 and apyrase significantly inhibited TCIPA, compared to single inhibitors. Combinations of antiplatelet drugs may represent a promising strategy to prevent cancer metastasis.

Original languageEnglish
Pages (from-to)675-680
Number of pages6
JournalOncology Letters
Volume5
Issue number2
DOIs
StatePublished - Feb 2013

Keywords

  • Adenosine diphosphate
  • Breast cancer
  • Glycoprotein-IIb/IIIa
  • Glycoprotein-Ib-IX
  • Thromboxane A2
  • Tumor cell-induced platelet aggregation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Inhibition of MCF-7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs'. Together they form a unique fingerprint.

Cite this